Crossref Citations
This article has been cited by the following publications. This list is generated based on data provided by Crossref.
Kapur, Shitij
Zipursky, Robert
Remington, Gary
Jones, Corey
McKay, Gordon
and
Houle, Sylvain
1997.
PET Evidence That Loxapine Is an Equipotent Blocker of 5-HT2 and D2 Receptors: Implications for the Therapeutics of Schizophrenia.
American Journal of Psychiatry,
Vol. 154,
Issue. 11,
p.
1525.
Ferrer, Marc
Soto-Angona, Óscar
Soler-Artigas, María
Ibáñez, Pol
Fadeuilhe, Christian
Palma-Álvarez, Raúl Felipe
Lidai, Raquefet
Vargas-Cáceres, Sebastian
Ángeles Torrecilla, María
López, Anna
and
Ramos-Quiroga, Josep Antoni
2022.
Inhaled Loxapine as a Rapid Treatment for Agitation in Patients with Personality Disorder: A Prospective Study on the Effects of Time.
Clinical Psychopharmacology and Neuroscience,
Vol. 20,
Issue. 3,
p.
482.
Hart, XM
Gründer, G
Ansermot, N
Conca, A
Corruble, E
Crettol, S
Cumming, P
Hefner, G
Frajerman, A
Howes, O
Jukic, M
Kim, E
Kim, S
Manisalco, I
Moriguchi, S
Müller, DJ
Nakajima, S
Osugo, M
Paulzen, M
Ruhe, HG
Scherf-Clavel, M
Schoretsanitis, G
Serretti, A
Spina, E
Spigset, O
Steimer, W
Süzen, HS
Uchida, H
Unterecker, S
Vandenberghe, F
Verstuyft, C
Zernig, G
Hiemke, C
and
Eap, CB
2024.
Optimisation of pharmacotherapy in psychiatry through therapeutic drug monitoring, molecular brain imaging and pharmacogenetic tests: focus on antipsychotics.
The World Journal of Biological Psychiatry,
p.
1.
Comments
No Comments have been published for this article.